Accessing the Benefits of GLP-1 RAs
Improving Cardiac and Renal Well-being
GLP-1 RAs are injectable glucose-lowering medications approved by the FDA for the treatment of adult patients with T2DM. In addition, GLP-1 RAs have been identified as an important drug class for not only glucose-lowering but also in reducing cardiovascular disease (CVD) events in adults with T2DM and high atherosclerotic cardiovascular disease (ASCVD) risk.1
GLP-1 RAs stimulate glucose-dependent insulin release in the gut after food intake and inhibit glucagon release with concomitant decreased gastric emptying and low risk of hypoglycemia. Important secondary effects include a decrease in appetite and food intake, which can lead to weight loss of 2 to 4 kg, and improved lipid levels, with decreased triglyceride levels and increased high-density lipoprotein levels.
Game Changers – The game that invites you to test your knowledge of GLP-1 RAs
It's time to test your knowledge about GLP-1 RAs and their benefits as they relate to type 2 diabetes.
Categories range from diagnostic criteria to Lifestyle Management. Test your knowledge and find out with this fun, engaging game.
Guidelines and Articles
- 2021 Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Hart Association/American Stroke Association | Stroke
- 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
- GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes | Circulation
- Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Assocation | Circulation
1Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 140: e596–e646. DOI: 10.1161/CIR. 0000000000000678
This program is supported by a medical educational grant from Novo Nordisk.